Product Details

Sandoz Solifenacin

Solifenacin Succinate
5 mg
Tablet


DIN/PIN/NPN

02399032

Manufacturer

Sandoz Canada Inc.

Formulary Listing Date

2015-11-26  

Unit Price

0.3041

Amount MOH Pays

0.3041

Coverage Status

Limited Use Product

ODB Formulary Therapeutic Classification

Therapeutic Note

NO

ATC Code

G04BD08

Interchangeable Products

DIN/ PIN/ NPN Brand name Unit Price Amount MOH pays
02277263 Vesicare 1.6892 0.3041
02397900 Teva-Solifenacin 0.3041 0.3041
02448335 Solifenacin Succinate Tablets 0.3041 0.3041
02458241 Solifenacin 0.3041 0.3041
02399032 Sandoz Solifenacin 0.3041 0.3041
02437988 Ran-Solifenacin 0.3041 0.3041
02493039 PRZ-Solifenacin 0.3041 0.3041
02417723 PMS-Solifenacin 0.3041 0.3041
02428911 Jamp Solifenacin Succinate 0.3041 0.3041
02424339 Jamp-Solifenacin 0.3041 0.3041
02446375 Auro-Solifenacin 0.3041 0.3041
02423375 Apo-Solifenacin 0.3041 0.3041
02422239 Act Solifenacin 0.3041 0.3041
02439344 Ach-Solifenacin Succinate 0.3041 0.3041
02529696 M-Solifenacin Succinate 0.3041 0.3041
 

LU Clinical Criteria

LU Code Auth. Period Clinical Criteria
290 Indefinite

For patients with urinary frequency, urgency or urge incontinence who have:

Failed to respond to behavioral techniques AND an adequate trial of oxybutynin with gradual dose escalation has shown to be either ineffective or resulted in unacceptable side effects.

Note: If after a trial of 2 weeks patients continue to experience similar side effects and no greater efficacy than oxybutynin, continued therapy with this more costly agent should be reassessed.

Antimuscarinic agents should be used with caution in the elderly due to potentially serious adverse effects (e.g. confusion, psychosis, acute urinary retention, constipation). Antimuscarinic agents should be avoided in older adults with pre-existing cognitive impairment (e.g., dementia) and those who are already using other drugs with significant anticholinergic effects (e.g., tricyclic antidepressants) in order to avoid a high overall anticholinergic drug burden.

 

EAP Criteria

NO

Product Monograph

View Monograph